Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

1104646

registered interest
date	25/03/2019
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisons: Arts and Literacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they provide (1) funding, and (2) other support to prisons to run arts and literacy programmes; if so, what; and how they assess the impact of such programmes.
tabling member printed	Lord Bird
uin	HL14771
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The National Criminal Justice Arts Alliance is part-funded through the Ministry of Justice grant to CLINKS. Whilst there is no separate budget to fund arts and literacy programmes, such activity has for many years been funded at local level through prison education budgets. Both the new education commissioning routes available to governors from 1 April make explicit provision for arts, literacy and other cultural activity as a means of engaging prisoners in learning. The activity also enables progression to higher levels, develops human and social capital, and improves life skills, employability and wellbeing, thereby helping to prevent re-offending.</p><p> </p><p>In 2016, ‘<em>Arts, culture and innovation in criminal justice settings: a guide for commissioners</em>’, published by the National Criminal Justice Arts Alliance, set out and summarised a growing body of evidence that demonstrates the positive impact of the arts in criminal justice settings in engaging, motivating and providing opportunities for people to develop new skills, as well as discover new ways of behaving and relating to others. On Friday 22 March 2019, the Ministry of Justice published a tool which arts organisations can use to measure the intermediate outcomes from activity they deliver within the criminal justice system. This will support them in demonstrating their effectiveness to commissioners.</p> answering member printed Lord Keen of Elie question first answered 02/04/2019 11:38:00 answering member 4538 label Biography information for Lord Keen of Elie
tabling member	4564 label Biography information for Lord Bird

1104647

registered interest
date	25/03/2019
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	Vocational Education: Qualifications
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Statement by Lord Agnew of Oulton on 19 March (HLWS1393), what part the BTEC National Diploma will play in the future examination framework and the current proposal to rigidly differentiate T levels qualifications from academic options.
tabling member printed	Lord Blunkett
uin	HL14772
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>As announced in the Written Statement on 19 March (HLWS1393), the first part of a two-part consultation reviewing qualifications at level 3 and below (excluding A levels and GCSEs) was launched on 19 March and will conclude on 10 June. The second part of the consultation will open later in the year.</p><p>The government is reviewing qualifications at level 3 and below for post-16 students and proposes to stop funding qualifications which are low quality and do not have a clear purpose. Analysis published by the department has highlighted over 12,000 courses that are currently on offer to young people at level 3 and below, with multiple qualifications available in the same subject areas.</p><p>As identified in the ‘Review of vocational education: the Wolf report’, the ‘Post-16 skills plan’ and the ‘Report of the independent panel on technical education’, many of these qualifications are poor quality and offer little value to students or employers. Although many qualifications were reformed to meet performance table criteria following Professor Wolf’s report, there is still much to do to raise the standard of all qualifications. Once the review has concluded, the government’s aim is that qualifications available alongside A levels, T levels and apprenticeships will be high quality and will set students on a clear path to a job, further education or training. All three reports are attached.</p> answering member printed Lord Agnew of Oulton attachment 1 file name Review_of-vocational_education_the_Wolf_report.pdf title Review_of-vocational_education_the_Wolf_report 2 file name Post_16_Skills_Plan.pdf title Post_16_Skills_Plan 3 file name Report_of_the_Independent_Panel_on_Technical_Education.pdf title Report_of_the_Independent_Panel_on_Technical_Educa question first answered 02/04/2019 16:08:12 answering member 4689 label Biography information for Lord Agnew of Oulton
tabling member	395 label Biography information for Lord Blunkett

1104652

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, whether they have made any further preparations on stockpiling (1) pharmacy, and (2) general sales list, medicines in the event that Article 50 is extended.
tabling member printed	Baroness Jolly
uin	HL14777
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14778 HL14779 HL14780 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4203 label Biography information for Baroness Jolly

1104653

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, whether they will update their guidance given to companies that supply (1) prescription only, (2) pharmacy, and (3) general sales list, medicines if Article 50 is extended.
tabling member printed	Baroness Jolly
uin	HL14778
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14777 HL14779 HL14780 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4203 label Biography information for Baroness Jolly

1104654

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions (1) the Department of Health and Social Care, and (2) NHS England have had with suppliers and manufacturers of general sales list (GSL) medicines to ensure the continued supply of GSL medicines that are important for the management of specific health conditions after the UK has left the EU.
tabling member printed	Baroness Jolly
uin	HL14779
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14777 HL14778 HL14780 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4203 label Biography information for Baroness Jolly

1104655

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what contingency plans have been put in place to ensure the continued supply of general sales list medicines that are important for the management of specific health conditions after the UK has left the EU.
tabling member printed	Baroness Jolly
uin	HL14780
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14777 HL14778 HL14779 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4203 label Biography information for Baroness Jolly

1104675

registered interest
date	25/03/2019
answering body	Department for International Trade
answering dept id	202
answering dept short name	International Trade
answering dept sort name	International Trade
hansard heading	Overseas Trade: Commonwealth
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to increase UK trade with Commonwealth countries after Brexit.
tabling member printed	Lord Taylor of Warwick
uin	HL14800
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>At last year’s Commonwealth Heads of Government Meeting (CHOGM), hosted by the UK, leaders adopted a six-point Connectivity Agenda for Trade and Investment to boost intra-Commonwealth trade to $2 Trillion by 2030. As Chair-In-Office, the UK is committed to working with our Commonwealth partners to achieve this target. That is why at CHOGM we launched three new programmes aimed at promoting inclusive intra-Commonwealth trade, cooperation on meeting standards and promoting trade by women-owned businesses. The UK will also be chairing the Commonwealth Trade Ministers meeting in October.</p><p> </p><p>Of our 52 Commonwealth partners, 44 currently benefit from development-friendly preferential access to the UK market. The Government is committed to seeking continuity for our current trade and investment relationships as we leave the EU, including those with Commonwealth countries.</p> answering member printed Baroness Fairhead question first answered 02/04/2019 12:32:05 answering member 4690 label Biography information for Baroness Fairhead
tabling member	1796 label Biography information for Lord Taylor of Warwick

1104682

registered interest
date	25/03/2019
answering body	Department for International Trade
answering dept id	202
answering dept short name	International Trade
answering dept sort name	International Trade
hansard heading	Imports: Israeli Settlements
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what trade agreements apply to goods coming from Israeli settlements (1) now, and (2) after the UK leaves the EU.
tabling member printed	Baroness Tonge
uin	HL14807
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The EU-Israel Trade Agreements and the transitioned UK-Israel Trade Agreement apply to the State of Israel. The UK has been clear that it does not recognise the Occupied Palestinian Territories (OPTs), including the settlements, as part of the State of Israel and that the OPTs are not covered by the UK-Israel Agreement.</p><p> </p><p>The EU-Palestinian Authority Interim Agreement and the transitioned UK-Palestinian Authority Interim Agreement apply to the territory of the West Bank and the Gaza Strip.</p><p> </p><p>Products produced in the Israeli settlements, located within the territories brought under Israeli administration since June 1967, are not entitled to benefit from preferential tariff treatment under either agreement.</p><p> </p> answering member printed Baroness Fairhead question first answered 02/04/2019 12:32:28 answering member 4690 label Biography information for Baroness Fairhead
tabling member	200 label Biography information for Baroness Tonge

1104692

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many oncology patients have been registered to receive treatment through the NHS in each year since 2010.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236365
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236367 236369 question first answered 02/04/2019 11:24:26 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104693

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Professions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many (a) nurses and (b) doctors are specifically employed within the oncology speciality.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236366
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS Digital publishes Hospital and Community Health Services workforce statistics. These include staff working in hospital trusts and clinical commissioning groups, but not staff working in primary care, local authorities or other providers.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 1,317 doctors with a speciality in clinical oncology and 985 doctors with a speciality in medical oncology. The figures include all doctors working in the specialty of oncology such as consultants, associate specialists, specialty doctors, doctors in training etc.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 2,093 nurses who work in an area of ‘clinical oncology’ and 1,237 nurses who work in an area of ‘medical oncology’. This data represents nurses who are working in services related to oncology, rather than nurses with specialist training in oncology.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:43:26 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon